Rodman & Renshaw initiated coverage of INmune Bio (INMB) with a Buy rating and $23 price target
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks
- INmune Bio treatment of epidermolysis bullosa receives FDA orphan designation
- Inmune Bio Announces Stock Options and Leadership Changes
- INmune Bio, OmniScience announce partnership to accelerate Alzheimer’s trial
- INmune Bio, OmniScience partner to accelerate trial with Vivo